Evidence map›Paper›PMID 40850594›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2026

Probable reactivation from latency of multidrug-resistant cytomegalovirus in a lung transplant recipient: A case report.

Julia A Wagner, Rama Yakubu, Adrian M Whelan, Steven R Hays, Helen C Stankiewicz Karita, Brian S Schwartz, Ajit P Limaye

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Julia A WagnerDivision of Infectious Diseases, Department of Medicine, University of California, San Francisco, California, USA. Electronic address: julia.wagner@ucsf.edu.
Rama YakubuDivision of Laboratory Medicine, Department of Medicine, University of California, San Francisco, California, USA.
Adrian M WhelanDivision of Nephrology, Department of Medicine, University of California, San Francisco, California, USA.
Steven R HaysDivision of Pulmonology, Department of Medicine, University of California, San Francisco, California, USA.
Helen C Stankiewicz KaritaDivision of Infectious Diseases, Department of Medicine, University of California, San Francisco, California, USA.
Brian S SchwartzDivision of Infectious Diseases, Department of Medicine, University of California, San Francisco, California, USA.
Ajit P LimayeDivision of Infectious Diseases, Department of Medicine, University of California, San Francisco, California, USA. Electronic address: ajit.limaye@ucsf.edu.

Funding

Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant candidates (COLT)U01AI163090 · NIAID · UNIVERSITY OF WASHINGTON · PI Don J Diamond, Cynthia E Fisher · 2021 to 2026
$17.4M
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and SepsisUH3HL147011 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BOECKH, MICHAEL J, LIMAYE, ABHIJIT PRAKASH · 2021 to 2024
$8.7M
Training in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4M
Kidney transplant Preemptive therapy or Prophylaxis (KPoP) for CMVPreventionin D+R- RecipientsR01AI184205 · NIAID · UNIVERSITY OF WASHINGTON · PI Daniel Conlon Brennan, Cynthia E Fisher · 2024 to 2026
$5.1M
NHLBI NIH HHS UH3 HL147011NIAID NIH HHS R01 AI184205NIAID NIH HHS T32 AI060530NIAID NIH HHS U01 AI163090
6 · The paper itself

Abstract

Whether ganciclovir-resistant cytomegalovirus (ganR-CMV) can establish latency and reactivate absent any selective drug pressure is unknown and has implications for selecting empiric antiviral therapy in patients with prior ganR-CMV. A CMV-seronegative patient underwent bilateral lung transplant from a CMV-seropositive donor and developed biopsy-confirmed CMV colitis with ganR-CMV (UL97 genotype: M460I, A594E; UL54 genotype: F412L, E756D) 4 years posttransplant despite prolonged valganciclovir prophylaxis. Foscarnet therapy led to CMV DNAemia clearance and disease resolution. Plasma CMV DNAemia by sensitive quantitative polymerase chain reaction was not detected in >100 samples over the next 16 years, when she underwent a kidney transplant from a CMV-seronegative donor. Valganciclovir was given for 3 days posttransplant, then switched to letermovir prophylaxis for 3 months. Two months later, CMV syndrome was diagnosed based on compatible symptoms, CMV DNAemia (2.7 × 10

Indexed as

Antiviral AgentsCytomegalovirusCytomegalovirus InfectionsDrug Resistance, Multiple, ViralLung TransplantationVirus ActivationVirus LatencyFemaleGanciclovirHumansPrognosisTransplant RecipientsAntiviral AgentsGanciclovirantiviral therapycytomegalovirusmultidrug-resistant cytomegalovirussolid organ transplantviral latency

Identifiers

PMID40850594
PMCPMC13157680

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.